It is true that the revenue has increased especially Australian revenue. But it is also true that costs has increased significantly. In fact far more than the revenue increase. The company has gone on record with the whole world told that it will be profitable during the fy 2020. If that happens, then definitely the SP rerate will happen with an exponential increase. We have 2 Qs left. To do so they will need to simultaneously focuss on both revenue and cost reduction.
Ann: Cellmid's Evolis Patent to be Granted in China, page-33
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.229M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 197835 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 7500 | 1 |
View Market Depth
| Last trade - 16.12pm 02/08/2024 (20 minute delay) ? |
| AN1 (ASX) Chart |
Day chart unavailable